Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000939
Chunk: 46

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 46
---
 the
right to make a public disclosure, in the form of a press release, public advertisement or otherwise, of such material, non-public information
without the prior approval by the Company; provided the Investor shall have first provided notice to the Company that it believes it has
received information that constitutes material, non-public information, the Company shall have at least two (2) Business Days to either
(i) demonstrate that such information is not material non-public information to the reasonable satisfaction of the Investor or (ii) publicly
disclose such material, non-public information prior to any such disclosure by the Investor. The Investor shall not have any liability
to the Company, any of its Subsidiaries, or any of their respective directors, officers, employees, shareholders or agents, for any such
disclosure, so long as the Investor has complied with this . The Company understands and confirms that the Investor
shall be relying on the foregoing covenants in effecting transactions in securities of the Company.

(g) . The Investor and the Company shall each maintain records showing the remaining Available Amount at any given time and the
dates and Purchase Amounts for each Fixed Purchase, VWAP Purchase and Additional VWAP Purchase or shall use such other method, reasonably
satisfactory to the Investor and the Company.

(h) Taxes.The Company shall pay any and all transfer, stamp or similar taxes that may be payable with respect to the issuance and delivery of Depositary Shares to the Investor made under this Agreement. For the avoidance of doubt, any other taxes incurred by the Investor (including any taxes on income resulting from the transactions contemplated by this Agreement) shall solely be the responsibility of the Investor.

(i) . The Company will use the net proceeds from the offering for any corporate purpose at the sole discretion of the Company.

(j) . During the term of this Agreement, the Company shall not enter into, announce or recommend to its shareholders any agreement,
plan, arrangement or transaction in or of which the terms thereof would restrict, materially delay, conflict with or impair the ability
or right of the Company to perform its obligations under the Transaction Documents, including, without limitation, the obligation of the
Company to deliver the Purchase Shares and the Commitment Shares to the Investor in accordance with the terms of the Transaction Documents.
Notwithstanding the foregoing, the Company shall not be in breach of this section if the Company enters into, announces or recommends
to its shareholders any business combination (or similar) whereby the shareholders of the Company immediately prior to the effective time
of